Market Size of Global Myomectomy Industry
| Study Period | 2018 - 2028 |
| Base Year For Estimation | 2021 |
| Forecast Data Period | 2024 - 2028 |
| CAGR | 9.80 % |
| Fastest Growing Market | Asia Pacific |
| Largest Market | North America |
Major Players
*Disclaimer: Major Players sorted in no particular order |
Need a report that reflects how COVID-19 has impacted this market and its growth?
Myomectomy Market Analysis
The myomectomy market is projected to register a CAGR of nearly 9.8% over the forecast period.
The impact of the COVID-19 pandemic is significant on the myomectomy market. With the surge of COVID-19 cases across the world, healthcare services diverted their resources toward the patients suffering from COVID-19. Guidelines and recommendations were provided for the management of patients during the pandemic. This resulted in hospitals prioritizing emergency procedures and delaying or postponing elective procedures, such as myomectomy surgery, leading to a backlog of patients waiting for their surgeries for months. A CovidSurg Collaborative study, 2020, estimated that around 28 million operations would be delayed during the peak 12-week disruption due to COVID-19, including 81.7% benign surgeries. With conditions returning to normal, myomectomy procedures are expected to recover gradually.
An increase in the number of patients suffering from uterine fibroids is anticipated to be the key factor contributing to the growth of the myomectomy market. According to the US Department of Health and Human Services, Office on Women’s Health, fibroids are common in women aged 40-50 years, and about 20-80% of women develop fibroids by the time they reach the age of 50 years. As per a research study published in 2018 involving women diagnosed with uterine fibroids, myomectomy and endometrial ablation remained the most opted surgical procedures. Another research study published in 2017, which included approximately 5,000 Italian women with uterine fibroids, showed that 95% of the surgeries performed included women in the age group of 36-55 years. Additionally, a rise in the number of minimally invasive surgical procedures due to fewer complications and reduced hospital stay is anticipated to drive the growth of the market. Technological advancements, such as the rise in the number of robotic and laparoscopic-assisted surgeries to deliver quality and efficient treatment, may also contribute to the growth of the myomectomy market.
Though the market holds several opportunities for growth in innovation and product developments, the myomectomy procedure has its own risks. According to a research study by Thieme, published in 2020, hemorrhage was the most common complication in abdominal myomectomy procedures, and 13% of hysteroscopic myomectomy procedures observed complications, such as excessive bleeding, uterine perforation, fluid overload, and postoperative infection. Research studies concluded that a higher recurrence rate of myoma was observed with laparoscopic myomectomy. Along with these factors, higher costs of new medical devices may restrict the growth of the myomectomy market.
